The potential of psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin in treating various neuropsychiatric disorders has received increased attention in recent times. These compounds are believed to exert their effects through the serotonin 5-HT2A receptor.
Cybin Irl Ltd. has described phenethylamine compounds acting as 5-HT2 receptor agonists reported to be useful for the treatment of lung diseases, cardiovascular disorders, inflammatory disorders, psychiatric disorders and neurological disorders.
Neurocrine Biosciences Inc. has divulged G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, bipolar disorder, vascular cognitive impairment, and Alzheimer’s, Parkinson’s and Huntington’s diseases, among other neurological disorders.
Astellas Pharma Inc. and Kotobuki Pharmaceutical Co. Ltd. have disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
CTNNB1 syndrome is a rare neurodevelopmental disorder that is caused by mutations in the gene encoding β-catenin, CTNNB1, which plays a critical role in neuronal development, synapse formation and brain maturation.
Neuroninn Biosciences Co. Ltd. has disclosed G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety, depression, Parkinson’s disease and more.
Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.
Adolore Biotherapeutics Inc. has offered an update on recent pipeline development progress as it advances nonopioid analgesic gene therapies for the treatment of chronic pain.
RSS
